z-logo
open-access-imgOpen Access
A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI
Author(s) -
Shih TzengeLien,
Lin KuanHung,
Chen RayJade,
Chen TingYu,
Kao WeiTing,
Liu JenWei,
Wang HsuehHsiao,
Peng HsienYu,
Sun YuYo,
Lu WanJung
Publication year - 2021
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.16886
Subject(s) - gpvi , chemistry , antithrombotic , platelet activation , platelet , pharmacology , thrombus , thrombin , biochemistry , integrin , medicine , receptor , immunology
Naphthalimide derivatives have multiple biological activities, including antitumour and anti‐inflammatory activities. We previously synthesized several naphthalimide derivatives; of them, compound 5 was found to exert the strongest inhibitory effect on human DNA topoisomerase II activity. However, the effects of naphthalimide derivatives on platelet activation have not yet been investigated. Therefore, the mechanism underlying the antiplatelet activity of compound 5 was determined in this study. The data revealed that compound 5 (5–10 μM) inhibited collagen‐ and convulxin‐ but not thrombin‐ or U46619‐mediated platelet aggregation, suggesting that compound 5 is more sensitive to the inhibition of glycoprotein VI (GPVI) signalling. Indeed, compound 5 could inhibit the phosphorylation of signalling molecules downstream of GPVI, followed by the inhibition of calcium mobilization, granule release and GPIIb/IIIa activation. Moreover, compound 5 prevented pulmonary embolism and prolonged the occlusion time, but tended to prolong the bleeding time, indicating that it can prevent thrombus formation but may increase bleeding risk. This study is the first to demonstrate that the naphthalimide derivative compound 5 exerts antiplatelet and antithrombotic effects. Future studies should modify compound 5 to synthesize more potent and efficient antiplatelet agents while minimizing bleeding risk, which may offer a therapeutic potential for cardiovascular diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here